Navigation Links
Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
Date:1/24/2008

Doctors Are Combining Portrait(R) Plasma with Fractionated Lasers Or in

Place of Surgery to Alleviate the Signs of Aging of the Eyes

WALTHAM, Mass., Jan. 24 /PRNewswire/ -- When it comes to the aging eye area, going under the knife is no longer the only option. According to the American Academy of Facial and Plastic Surgery, surgeons are seeing a more educated patient who is interested in non-surgical options to obtain the best results. One of the most requested aesthetic treatments is wrinkle reduction and tightening around the eyes and the excess tissue of the upper eyelid. For patients who experience sagging, droopy eye lids, wrinkles and puffiness, blepharoplasty (eyelid surgery) is no longer the only option to obtain a more youthful eye area.

One solution offered by Dr. Brian Biesman, Ophthalmic Plastic and Reconstructive Surgeon of Nashville Centre for Laser and Facial Surgery in Nashville, Tennessee, is a cosmetic combination that helps patients reap maximum benefits from their treatment; blepharoplasty, Portrait Plasma, a novel plasma skin regeneration technology, and injectables such as Botox and fillers.

"Blepharoplasty removes the excess tissue and skin, but Portrait Plasma improves skin quality. It smoothes fine lines and treats both wrinkles and sun damage, which surgery alone cannot do," according to Dr. Biesman. Additionally he indicated injectables may be used to relax the muscles and then, in some cases, filler may be used to enhance volume. Physicians are also combining Portrait with other aesthetic procedures, such as fractionated lasers, a popular treatment that does not meet patient's demands for improvement in the peri-orbital area. Richard Fitzpatrick, MD from La Jolla Cosmetic Surgery Centre combines Portrait(R) Plasma with fractional laser for further results on the face. At times he chooses Portrait Plasma for treating eyes over other devices in his practice remarking, "Eyelid skin is uniquely suited for
'/>"/>

SOURCE Rhytec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
2. GSK Does Not Option XL784 for Further Development
3. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
4. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
5. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
8. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
9. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
(Date:11/24/2008)... Takeda Pharmaceutical Company Limi... Research & Development Center, Inc., U.S., an...e of the U.S. Food and Drug Administration (FDA) r...e treatment of hyperuricemia in patients with gout...th one panel member abstaining. The vote followed ...
(Date:11/24/2008)...Call/ -- Leaders of Schering-Plough Corporation (N...s on the company,s research pipeline, highlighting...new entities in clinical trials or under regulator... "Research and development is adding strength and ...sformation," said Fred Hassan, chairman and CEO. ...
(Date:11/24/2008)... and long-term commitment to hepatitis research ,...stCall/ -- Schering-Plough Corporation (NYSE: SG..., its lead investigational oral hepatitis C protea...The company believes boceprevir has the potential ...inhibitor for treating chronic hepatitis C. The c...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9AIDS Stopped in Haiti Before U S 4956 1AIDS Stopped in Haiti Before U S 4956 2AIDS Stopped in Haiti Before U S 4956 3Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 1Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 2Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 1Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 2Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 3Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 4Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 5Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 6Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 7Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 8Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 9Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 10Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 11Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 12Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 13Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 14Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 15Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 16Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 17Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 18Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 19Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 20Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 21Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 22Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 23Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 24Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 25Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 26Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 27Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 28Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 29ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 1ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 2ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 3ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 4ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 5ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 6ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 7ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 8ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 9ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 10
... BOULDER, Colo.--(BUSINESS WIRE)--Jun 20, 2007 - A...hase 1 clinical data on its MEK,inhibitor, ARRY-16...were presented at the Annual European Congress of ...he International Association,of Inflammation Socie... Copenhagen, Denmark., ARRY-162 / MEK Inhibitor Ph...
... VIENNA, Va., June 20, 2007 /PRNewswire/ -- Modig... successful completion of,pharmacokinetic and phar...ng human growth hormone, long-acting interferon be...armacodynamic and pharmacokinetic pre-clinical,exp...g-acting,proteins, indicating a potential administ...
Other Medicine Technology:Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 2Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 3Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 4Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 2Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 3Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 4
(Date:12/1/2008)...rstCall/ -- Senetek PLC,(OTC Bulletin Board: SNKT...pment of technologies that target the science of h... AG, specialists in the fields of strategic,devel... offices in Zurich,Bern and Geneva has published...search Report, available in the "Investors" sectio...
(Date:12/1/2008)...against plantar fasciitis, researchers say , ...n researchers say they,ve developed a fast, effect...ondition known as plantar fasciitis. , Using a ...ns guided by ultrasound, the researchers say their...ckling a condition that afflicts about one million...
(Date:12/1/2008)...ohnson Public Service Announcement (PSA) focuses o... PARK, Ill., Dec. 1 T...he Magic Johnson Foundation and Abbott are cal...mily and friends about HIV/AIDS and its impact on ...rking tool allows Facebook users to stand with Mag...
(Date:12/1/2008)...e Cross Blue Shield of Michigan,provided more tha...nformation,today to Michigan Attorney General Mik...on about Michigan,s individual health insurance ma...n,s individual health insurance market,and escala...,s last-resort,insurance carrier, in its individu...
Breaking Medicine News(10 mins):Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 2Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 3Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 4Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 5Health News:Blue Cross Blue Shield of Michigan Answers Attorney General 2Health News:Blue Cross Blue Shield of Michigan Answers Attorney General 3
... by addiction specialists and published in Lancet ...trimental to health than class A drugs. Prof David.... This study rates alcohol as the fifth most da...d and safety. Tobacco is considered more addictiv...
...disease tuberculosis is on the march. Figures rele...an increase by 2 percent in number of TB cases ove...orld TB Day, which falls on the 24th of March, a...ngland, Wales and Northern Ireland. London contin...
...ening Committee of UK are considering ways to regu...According to Sir Muir Gray, program director of th...ence of these screening programs creating unwant...tant pressure being put on the National Health Ser...
.... Steriani Elavsky, women passing through their me...ife// when they exercised. The improvements in hea...tive effect on their perceived quality of life. T...tive menopausal women who were divided into three ...
Other Medicine News:Health News:TB Cases on the Rise 2
Inquire
Inquire
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS
...ew device for skin extension.Thanks to its titaniu...ws a constant and powerful creep reaction of the t... effectiveness makes the FRECHET EXTENDER® a s...ys. Furthermore it is invisible when implanted. Ma...
Medicine Products: